Skip to search formSkip to main contentSkip to account menu

PD 134308

Known as: PD-134308, PD134308 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (5)

Anti-Anxiety AgentsAntineoplastic AgentsHormone AntagonistsIndoles
CI 988analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Functional neuroanatomy of the ventral striopallidal GABA pathway New sites of intervention in the treatment of schizophrenia
  • W. O’Connor
  • Journal of Neuroscience Methods
  • 2001
  • Corpus ID: 6999706
1996
1996
Evidence for a differential cholecystokinin-B and -A receptor regulation of gaba release in the rat nucleus accumbens mediated via dopaminergic and cholinergic mechanisms
1994
1994
H3-receptor regulation of vascular gastrin and somatostatin releases by the isolated rat stomach.
We have studied the effects of the H3-receptor agonist (R) alpha-methylhistamine [(R) alpha-MeHA] and the H3-receptor antagonist… 
1992
1992
CCK modulates inhibitory synaptic transmission in the solitary complex through CCKB sites.
The CCKB antagonists L-365, 260 and PD134308 and the CCKA antagonist L-364, 718 were applied to neurones of the rat solitary… 
Highly Cited
1991
Highly Cited
1991
Anxiolytic effects of CCK-B antagonists
Highly Cited
1991
Highly Cited
1991
Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
The effect of neuropeptide cholecystokinin (CCK) receptor agonists and antagonists was examined in the rat elevated X-maze model… 
1991
1991
Development of CCK-B antagonists
1991
1991
Inhibition of food intake by omeprazole in the chicken.
Highly Cited
1990
Highly Cited
1990
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
PD134308 and PD135158 are potent and selective antagonists at the cholecystokinin type B (CCK-B) receptors with IC50 values of 1… 
Highly Cited
1990
Highly Cited
1990
PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive…
The effects of systemic PD134308 [0.1-3 mg/kg; an antagonist of the cholecystokinin (CCK) type B receptor], morphine, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)